Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (K D =0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer.
体外研究(In Vitro)
Ganitumab (AMG 479; 0.032-500 nM; 10 分钟; CT26 细胞) 结合 mIGF1R 并抑制 IGF1 和 IGF2 介导的 mIGF1R 的激活。 has not independently confirmed the accuracy of these methods. They are for reference only.Western Blot AnalysisCell
体内研究(In Vivo)
Ganitumab (AMG 479; 1 mg/剂; i.p; Na?ve 和荷瘤小鼠) 抑制 IGF1 诱导的小鼠肺中 mIGF1R 的激活。
Ganitumab (300 μg/剂; i.p.; 雌性无胸腺裸鼠) 减少外周血中性粒细胞。
Ganitumab (300 μg/剂; i.p.;雄性无胸腺裸鼠) 导致雄性小鼠糖耐量受损,并增加血清中 mGH,mIGF1 和 mIGFBP3。 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Moody G, et, al. IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice. J Endocrinol. 2014 Mar 17;221(1):145-55.